Roth Affirms TG Therapeutics (TGTX) at 'Focus Pick'; Sees Strong Results in 2016

TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update

Ended 2015 in a Strong Financial Position, With More Than $100 Million in Cash and Investments

Investor Conference Call to be Held Today, Monday, March 7, 2016 at 4:30pm ET  

NEW YORK, March 07, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2015 and provided recent company developments along with a business outlook for 2016.

Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, stated, "2015 was a transformational year for our Company as we launched our first registration... More

TG Therapeutics, Inc. to Present at Upcoming Investment Conferences

NEW YORK, March 07, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX) today announced its participation at two upcoming investment conferences. Michael S. Weiss, the Companys Executive Chairman and Interim Chief Executive Officer, is scheduled to present tomorrow Tuesday, March 8, 2016 at 11:35am ET, at the Raymond James & Associates 37th Annual Institutional Investors Conference, being held at the JW Marriott Grande Lakes in Orlando, Florida.  Michael... More

TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2015 Financial Results and Business Update

NEW YORK, March 04, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, March 7, 2016 at 4:30pm ET to discuss results for the fourth quarter and year-end 2015, and provide a business outlook for 2016.  Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029... More